Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials) - Concepedia

Concepedia

Publication | Open Access

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

DOI Full Paper Access

119

Citations

36

References

2023

Year

Antonio Anzueto, Igor Barjaktarević, Thomas M. Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard, Frank C. Sciurba

American Journal of Respiratory and Critical Care Medicine

Abstract

gov identifier NCT04542057, EudraCT identifier 2020-002069-32).

References

	Year	Citations

Page 1